Investment will strengthen company’s clinical capabilities and treatments for musculoskeletal (MSK) conditions and chronic obstructive pulmonary disease (COPD)

Contributed by: Peter Lasinger, 3VC venture capital fund Partner and Kaia Health Board Advisor

With the new product launch, Kaia Health will offer next-generation MSK care that integrates with the existing care landscape.

How clinical evidence can help providers and employers choose the best digital MSK therapies for their populations

Historic agreement with Chiesi Group forges innovative digital therapeutics-pharmaceutical partnership on at-home respiratory care therapy solution, builds foundation for U.S. market

Highly individualized coaching experience and exercise goals maximize therapeutic effectiveness while reducing MSK medical spend.